Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin 50 mg versus 150 mg for invasive candidiasis in adults
2005-004504-36Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2005
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of caspofungin in invasive candidiasis (2 arms), sponsored by Merck & Co. Primary endpoint: Primary safety endpoint. Started Nov 2005; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on 2005-004504-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004504-36.